Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Bone Marrow Transplant

Donor Stem Cell Transplant in Treating Patients With Fanconi's Anemia (FHCRC-2064)
Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study
Status Conditions Phase Study ID
Recruiting Fanconi Anemia
Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Phase I/II FHCRC-2064
NCT00453388
Summary

The purpose of this study is to test a nonmyeloablative bone marrow transplant (one that uses milder or lower doses of drugs or radiation) for patients with Fanconi Anemia who do not have an HLA-matched, related donor (a family member with the same tissue type). This transplant uses either a donor who is related to the patient but has a different tissue type or a donor who is not related to the patient but has a similar tissue type.

Adult participants will receive treatment at the Seattle Cancer Care Alliance (SCCA) outpatient clinic. If hospitalization is needed while in Seattle, adult participants will be admitted to the University of Washington Medical Center (UWMC). All pediatric patients will be admitted for their bone marrow transplant to Children's Hospital and Regional Medical Center (CHRMC) and once discharged, will be followed at the SCCA outpatient clinic.

Treatment on this study will last about 2 months, with close follow-up for about 7 months after transplant. Follow-up may continue for up to five years after treatment has stopped.


Investigator
Hans-Peter Kiem, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)

1. Patient must have a diagnosis of Fanconi Anemia with at least one of the following:

a.  Has Bone Marrow Failure (2 cell lines affected or 1 cell line affected with life-threatening event)

b.  Requires blood transfusions due to any type of Bone Marrow Failure

c.  Has Leukemia (must be in remission) or Myelodysplastic Syndrome (MDS)

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

1. HLA-matched, related donor available

2. Severe disease other than Fanconi Anemia

3. HIV-positive.

4. Pregnant or breast-feeding.

5. Leukemia relapse (where applicable)

Other exclusion criteria may apply.

Last Updated
March 17, 2011
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.